MedTrace Logo

Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration

NCT00940641 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2011-01-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of AZD7325 after intravenous and 14C labeled oral dose

Conditions

  • Absorption
  • Distribution
  • Metabolism
  • Excretion

Interventions

DRUG

AZD7325

IV Dose

DRUG

AZD7325

oral dose

Sponsors & Collaborators

Principal Investigators

  • Raj Chetty, MBBS, MD, FRCPath. · AstraZeneca Alderly Park CPU

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00940641 on ClinicalTrials.gov